This company has been marked as potentially delisted and may not be actively trading. XTL Biopharmaceuticals (XTLB) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsEarningsHeadlinesShort InterestTrendsBuy This Stock XTLB vs. GDTC, TPST, CARA, PULM, KALA, CASI, ENLV, HILS, ABVC, and CLNNShould you be buying XTL Biopharmaceuticals stock or one of its competitors? The main competitors of XTL Biopharmaceuticals include CytoMed Therapeutics (GDTC), Tempest Therapeutics (TPST), Cara Therapeutics (CARA), Pulmatrix (PULM), KALA BIO (KALA), CASI Pharmaceuticals (CASI), Enlivex Therapeutics (ENLV), Hillstream BioPharma (HILS), ABVC BioPharma (ABVC), and Clene (CLNN). These companies are all part of the "pharmaceutical preparations" industry. XTL Biopharmaceuticals vs. CytoMed Therapeutics Tempest Therapeutics Cara Therapeutics Pulmatrix KALA BIO CASI Pharmaceuticals Enlivex Therapeutics Hillstream BioPharma ABVC BioPharma Clene XTL Biopharmaceuticals (NASDAQ:XTLB) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment, community ranking and analyst recommendations. Does the MarketBeat Community favor XTLB or GDTC? XTL Biopharmaceuticals received 75 more outperform votes than CytoMed Therapeutics when rated by MarketBeat users. However, 100.00% of users gave CytoMed Therapeutics an outperform vote while only 71.82% of users gave XTL Biopharmaceuticals an outperform vote. CompanyUnderperformOutperformXTL BiopharmaceuticalsOutperform Votes7971.82% Underperform Votes3128.18% CytoMed TherapeuticsOutperform Votes4100.00% Underperform VotesNo Votes Is XTLB or GDTC more profitable? Company Net Margins Return on Equity Return on Assets XTL BiopharmaceuticalsN/A N/A N/A CytoMed Therapeutics N/A N/A N/A Which has preferable valuation and earnings, XTLB or GDTC? XTL Biopharmaceuticals has higher earnings, but lower revenue than CytoMed Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXTL BiopharmaceuticalsN/AN/A-$1.78MN/AN/ACytoMed Therapeutics$69.50K347.08-$3.13MN/AN/A Do institutionals & insiders have more ownership in XTLB or GDTC? 4.4% of XTL Biopharmaceuticals shares are held by institutional investors. Comparatively, 0.0% of CytoMed Therapeutics shares are held by institutional investors. 29.0% of XTL Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media favor XTLB or GDTC? In the previous week, XTL Biopharmaceuticals' average media sentiment score of 0.00 beat CytoMed Therapeutics' score of -0.91 indicating that XTL Biopharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment XTL Biopharmaceuticals Neutral CytoMed Therapeutics Negative Do analysts rate XTLB or GDTC? CytoMed Therapeutics has a consensus target price of $5.00, indicating a potential upside of 126.76%. Given CytoMed Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe CytoMed Therapeutics is more favorable than XTL Biopharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XTL Biopharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00CytoMed Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, XTLB or GDTC? XTL Biopharmaceuticals has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Comparatively, CytoMed Therapeutics has a beta of -0.31, indicating that its share price is 131% less volatile than the S&P 500. SummaryXTL Biopharmaceuticals beats CytoMed Therapeutics on 6 of the 11 factors compared between the two stocks. Get XTL Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XTLB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XTLB vs. The Competition Export to ExcelMetricXTL BiopharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.16M$6.47B$5.33B$8.31BDividend YieldN/A2.64%5.20%4.10%P/E RatioN/A8.4026.7219.60Price / SalesN/A258.84395.56117.96Price / CashN/A65.8538.3234.62Price / Book2.686.416.764.50Net Income-$1.78M$143.73M$3.23B$248.40M XTL Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XTLBXTL BiopharmaceuticalsN/A$1.10-2.7%N/AN/A$6.16MN/A0.00N/AGDTCCytoMed Therapeutics1.4774 of 5 stars$2.25-3.4%$5.00+122.2%+5.3%$24.62M$69,501.000.00N/AGap UpTPSTTempest Therapeutics1.9586 of 5 stars$6.66-2.8%$30.00+350.5%-85.2%$24.52MN/A-4.3520Gap DownCARACara Therapeutics1.5904 of 5 starsN/A$72.00+∞N/A$24.33M$7.14M-0.2580Gap DownHigh Trading VolumePULMPulmatrix0.5373 of 5 stars$6.50+0.3%N/A+228.6%$23.73M$7.81M-2.4620Analyst ForecastGap UpKALAKALA BIO3.0739 of 5 stars$3.64-0.8%$15.00+312.1%-37.5%$23.49M$3.89M-0.2930Negative NewsAnalyst ForecastCASICASI Pharmaceuticals4.0476 of 5 stars$1.91-1.7%$4.00+109.7%-45.4%$23.46M$28.54M-0.86180News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionGap UpENLVEnlivex Therapeutics2.0544 of 5 stars$0.99-1.0%$10.00+910.1%-33.2%$23.41MN/A-1.0170HILSHillstream BioPharmaN/A$1.33+0.4%N/A+245.7%$23.41MN/A-1.851Gap DownABVCABVC BioPharma0.2039 of 5 stars$1.38-6.8%N/A+13.1%$23.15M$508,384.00-1.6030CLNNClene2.1037 of 5 stars$2.63+2.3%$40.00+1,420.9%-66.4%$23.09M$350,000.00-0.50100 Related Companies and Tools Related Companies CytoMed Therapeutics Competitors Tempest Therapeutics Competitors Cara Therapeutics Competitors Pulmatrix Competitors KALA BIO Competitors CASI Pharmaceuticals Competitors Enlivex Therapeutics Competitors Hillstream BioPharma Competitors ABVC BioPharma Competitors Clene Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XTLB) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XTL Biopharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share XTL Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
